Jazz Pharmaceuticals plc (NASDAQ: JAZZ) kicked off on Tuesday, up 5.63% from the previous trading day, before settling in for the closing price of $111.03. Over the past 52 weeks, JAZZ has traded in a range of $99.06-$137.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 15.52%. While this was happening, its average annual earnings per share was recorded 6.72%. With a float of $59.62 million, this company’s outstanding shares have now reached $62.26 million.
The extent of productivity of a business whose workforce counts for 2800 workers is very important to gauge. In terms of profitability, gross margin is 77.56%, operating margin of 16.63%, and the pretax margin is 7.61%.
Jazz Pharmaceuticals plc (JAZZ) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Jazz Pharmaceuticals plc is 3.45%, while institutional ownership is 95.48%. The most recent insider transaction that took place on Sep 06 ’24, was worth 152,703. In this transaction SVP, Technical Operations of this company sold 1,410 shares at a rate of $108.30, taking the stock ownership to the 14,531 shares. Before that another transaction happened on Sep 06 ’24, when Company’s Officer proposed sale 2,691 for $110.00, making the entire transaction worth $296,010.
Jazz Pharmaceuticals plc (JAZZ) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 6.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.49% during the next five years compared to -3.53% drop over the previous five years of trading.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
Take a look at Jazz Pharmaceuticals plc’s (JAZZ) current performance indicators. Last quarter, stock had a quick ratio of 1.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.85. Likewise, its price to free cash flow for the trailing twelve months is 6.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.60, a number that is poised to hit 5.52 in the next quarter and is forecasted to reach 21.51 in one year’s time.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
The latest stats from [Jazz Pharmaceuticals plc, JAZZ] show that its last 5-days average volume of 0.61 million was inferior to 0.68 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 80.13%. Additionally, its Average True Range was 2.69.
During the past 100 days, Jazz Pharmaceuticals plc’s (JAZZ) raw stochastic average was set at 97.38%, which indicates a significant decrease from 97.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.67% in the past 14 days, which was lower than the 27.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $110.62, while its 200-day Moving Average is $113.70. Now, the first resistance to watch is $119.53. This is followed by the second major resistance level at $121.77. The third major resistance level sits at $126.02. If the price goes on to break the first support level at $113.04, it is likely to go to the next support level at $108.79. The third support level lies at $106.55 if the price breaches the second support level.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Key Stats
The company with the Market Capitalisation of 7.24 billion has total of 63,062K Shares Outstanding. Its annual sales at the moment are 3,834 M in contrast with the sum of 414,830 K annual income. Company’s last quarter sales were recorded 1,024 M and last quarter income was 168,570 K.
